Today: 4 March 2026
Subscribe
Browse Category

Stock Market 30 October 2025

Intel (INTC) Stock Soars 90% to 18-Month High on AI Boom, $15B Lifeline – Will the Rally Last?

Intel (INTC) Stock Soars 90% to 18-Month High on AI Boom, $15B Lifeline – Will the Rally Last?

Intel stock has surged 85–90% year-to-date, hitting an 18-month high near $42 after a surprise Q3 return to profit and $13.7 billion in revenue. The U.S. government, Nvidia, and SoftBank invested $15 billion in 2025, with Washington taking a 10% stake. New CEO Lip-Bu Tan is steering Intel toward AI and advanced manufacturing. Analysts warn the stock’s valuation, now ~70× forward earnings, far exceeds peers.
30 October 2025
···
Ambev’s Profit Soars 36% in Q3 – Buyback Announced as ABEV Stock Eyes Rally

Ambev’s Profit Soars 36% in Q3 – Buyback Announced as ABEV Stock Eyes Rally

Ambev S.A. reported Q3 net income of 4.86 billion reais, up 36% year-on-year and well above analyst forecasts. Beer volumes fell 5.9%, but higher prices kept revenue flat; EBITDA was R$7.06 billion, beating estimates. The board approved a buyback of up to 208 million shares. Shares traded around $2.25 after results, with analysts split on outlook amid sector headwinds.
30 October 2025
··
BYD’s European EV Invasion – Boom in Sales but Stock Takes a Hit

BYD Stock Plunges 30% on Profit Slump – Is the EV Price War to Blame?

BYD reported a 32.6% drop in Q3 net profit to ¥7.8 billion and cut its 2025 sales target by 16% on Oct. 30. The Hong Kong stock slid to HK$104.20, down about 30% from May highs, erasing over $45 billion in market value. Q3 deliveries in China fell for the first time since 2020 amid fierce EV price competition. Overseas, BYD registrations in Europe surged nearly fivefold in September.
30 October 2025
··
FMC Stock Plunges Over 40% to Multi-Year Low After Shock Loss and Dividend Cut – Is a Turnaround Possible?

FMC Stock Plunges Over 40% to Multi-Year Low After Shock Loss and Dividend Cut – Is a Turnaround Possible?

FMC Corp shares plunged 42% to $16, their lowest since 2016, after the company posted a $569 million quarterly loss and slashed its dividend by 80%. Revenue fell 49% year-over-year, hit by a $510 million write-down tied to its India business. The company cut its 2024 outlook and announced President Ronaldo Pereira will step down December 15. Analysts downgraded the stock and trimmed price targets.
30 October 2025
·
Nvidia’s Record $5 Trillion Surge: AI Mega-Deals Propel NVDA Stock – Is $300 Next?

Nvidia’s Record $5 Trillion Surge: AI Mega-Deals Propel NVDA Stock – Is $300 Next?

Nvidia’s market value topped $5 trillion this week as shares hit $207, following major AI chip deals and new supercomputer plans. Revenue jumped 56% last quarter to $46.7 billion, with the company forecasting 54% growth next quarter. Rival chipmakers AMD and Qualcomm also surged on new AI partnerships, but analysts say Nvidia still dominates supply. Wall Street remains bullish, though some warn the stock is “priced for perfection.”
30 October 2025
··
Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

Altria reported Q3 net revenue down 3% to $6.07 billion and adjusted EPS of $1.45, matching estimates. Shares fell nearly 4% pre-market, trading about 10% below recent highs. The company doubled its buyback program to $2 billion and raised its 2025 earnings outlook floor. Cigarette and oral tobacco sales declined, while NJOY e-cigarette sales remain halted due to a patent dispute.
30 October 2025
···
Cava Stock Plunges to 52-Week Low – Bargain Buy or More Pain Ahead?

Cava Stock Plunges to 52-Week Low – Bargain Buy or More Pain Ahead?

Cava Group shares fell to a 52-week low of $54.93 on Oct. 30, down nearly 55% in a year and 62% below post-IPO highs. Revenue rose 24% in the first half of 2025, but same-store sales growth slowed to 2.1% last quarter. Analysts remain split, with price targets ranging from $37.50 to $100. The company continues to expand, recently opening locations in Miami and Detroit.
30 October 2025
·
Mario, Donkey Kong, Metroid – Is Nintendo Assembling Its Own “Avengers” Cinematic Universe?

Mario, Donkey Kong, Metroid – Is Nintendo Assembling Its Own “Avengers” Cinematic Universe?

Nintendo announced The Super Mario Galaxy Movie for April 2026, with the original cast returning, after The Super Mario Bros. Movie grossed over $1 billion worldwide. A live-action Zelda film is in development for 2027, and a Donkey Kong animated spin-off is underway. Rumors point to a Metroid movie, with Brie Larson lobbying for the lead. Nintendo stock hit record highs in 2025, boosted by Switch 2 and film prospects.
30 October 2025
·
Trump-Xi Trade Truce Sends Stocks Tumbling – Markets Brace for Tech Earnings and Fed Moves

Trump-Xi Trade Truce Sends Stocks Tumbling – Markets Brace for Tech Earnings and Fed Moves

Trump and Xi agreed to a one-year pause on new tariffs and rare-earth export curbs at the Busan summit. U.S. tariffs on China will drop to 47%, and China will resume buying U.S. soybeans. U.S. stock futures slipped Thursday after record highs, as Fed Chair Powell signaled caution on further rate cuts. Alphabet shares jumped on strong earnings, while Microsoft and Meta fell premarket.
30 October 2025
········
Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Mastercard reported Q3 2025 revenue of $8.60 billion, up 17% year-over-year, with net profit rising 20% to $3.96 billion. Shares traded near $570 in October, up about 8% year-to-date and close to their 52-week high. The company announced support for major US dollar stablecoins and is in late-stage talks to acquire crypto firm ZeroHash for up to $2 billion. About 80% of analysts rate the stock a buy.
30 October 2025
···
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Intensity Therapeutics shares surged nearly 200% on Oct. 30, 2025, after Phase 1/2 trial results for INT230-6 showed a 75% disease control rate and median survival of 11.9 months in advanced cancer patients. The stock traded around $0.27 with a market cap near $13.1 million and daily volume spiking to 279 million shares. INT230-6 is in late-stage trials for sarcoma and breast cancer.
30 October 2025
·
Trump Touts “Tremendous” Soybean Deal with China – Farmers Cautious as Details Remain Vague

Trump Touts “Tremendous” Soybean Deal with China – Farmers Cautious as Details Remain Vague

President Trump announced China will buy large amounts of U.S. soybeans after meeting President Xi in Busan, but China offered no specific purchase commitments. U.S. soybean futures spiked, then fell 2.2% on uncertainty, settling near $10.80 per bushel Friday. Midwest farmers report billions lost from China’s near-total boycott. Analysts say China is still buying mostly Brazilian soybeans and warn U.S. tariffs remain unchanged.
30 October 2025
Citi Stuns Markets by Slashing Loan Rate – See What’s Next for Borrowers & Stocks

Citi Stuns Markets by Slashing Loan Rate – See What’s Next for Borrowers & Stocks

Citibank lowered its base lending rate to 7.00% from 7.25%, effective October 30, after the U.S. Federal Reserve cut its policy rate by 25 basis points to 3.75–4.00% on October 29. Citigroup shares fell 2.2% to $99 following the news, despite a strong year-to-date rally. Indian banks also trimmed lending rates in October, while the Reserve Bank of India kept its repo rate steady at 5.50%.
30 October 2025
··
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Novo Nordisk launched a hostile bid for Metsera on Oct. 30, 2025, offering up to $9 billion and topping Pfizer’s earlier $7.3 billion deal. Metsera shares jumped about 19% in premarket trading. The board called Novo’s offer “superior,” giving Pfizer four days to respond. A law firm began investigating whether the original Pfizer deal was fair to shareholders.
30 October 2025
····
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen shares fell about 2.6% after hours Oct. 30 following Q3 results that beat estimates, with revenue at $2.53 billion and adjusted EPS of $4.81. The company cut 2025 non-GAAP EPS guidance to $14.50–$15.00, citing a $1.25 per-share R&D charge. Leqembi sales reached $121 million, up 80% year-over-year. Biogen licensed Vanqua Bio’s inflammation drug for up to $1.06 billion.
30 October 2025
··
GLE Stock Skyrockets 50%: Key Facts & What’s Next

GLE Stock Skyrockets 50%: Key Facts & What’s Next

Global Engine Group (Nasdaq: GLE) closed at $0.6526 on Oct. 29, then surged to nearly $1.00 in early Oct. 30 trading, a gain of about 50%. No news or filings explained the spike. GLE, a small Hong Kong tech firm, reported a sharp drop in revenue and a net loss for its latest fiscal year. The stock remains down 62% for 2025.
30 October 2025
·
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna shares closed at $299.12 on Oct 29, down 3% for the week, before rising to $303 in Oct 30 premarket trading. The company reported Q3 revenue of $69.7 billion and net income of $1.87 billion, beating forecasts and reaffirming its full-year outlook. Cigna launched a new pharmacy benefit model and Evernorth invested $3.5 billion in Shields Health. Analyst consensus remains bullish with a $370–$377 price target.
30 October 2025
···
1 … 1,227 1,228 1,229 1,230 1,231 … 1,332
Go toTop